Výsledky vyhledávání

Akademický článek

Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III–IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib/II study

Autor: Lina Yin, Wei Jiang, Shuai Liu, Yi Fu, Lin Zhou, Xuan Pei, Shuang Ye, Wenbin Shen, Huijuan Yang, Boer Shan

Publikováno v: BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)

Abstract Background Neoadjuvant chemotherapy may be considered for patients with ovarian cancer (OC) whose tumors are deemed unlikely to be completely cytoreduced to no gross residual disease (R0) or who are poor surgical candidates. This Ib/II study

Externí odkaz: https://doaj.org/article/b1f4c536d6d54eba85e05685b2d3d915

Zobrazit plný text záznamu

Plný text ve formátu HTML

Kniha

Osídlení lidu kultury s moravskou malovanou keramikou na území Modřic a v blízkém okolí na základě analýzy keramiky = The Moravian Painted Ware Culture settlement in the territory of Modřice based on pottery analysis / Alena Hrbáčková.

Autor: Nejedlá, Alena, 1979-

Akademický článek

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Autor: Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, Lucie Oberic, Olivier Chinot, Franck Morschhauser, Frédéric Peyrade, Roch Houot, Khê Hoang-Xuan, Hervé Ghesquieres, Carole Soussain

Publikováno v: Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-13 (2024)

Abstract Background Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results at relap

Externí odkaz: https://doaj.org/article/e4b9f07718ad41fb8fee30f518f61b80

Zobrazit plný text záznamu

Akademický článek

Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2

Publikováno v: Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-5 (2023)

Abstract In retrospective studies, metformin use has been associated with better clinical outcomes in diabetic patients with advanced, well-differentiated neuroendocrine tumors (WDNETs). However, prospective evidence of metformin safety and activity

Externí odkaz: https://doaj.org/article/1fcb7b069e624b61b3c438f1291779ca

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

Publikováno v: Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)

Abstract Mivavotinib (TAK‐659/CB‐659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti‐PD‐1 therapy in cancer models. This dose‐escalation/expansion study inv

Externí odkaz: https://doaj.org/article/543c6b5130f7472f8fd3b9ea9ea6f7e2

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor

Autor: Qi Zhang, Ting Deng, Fen Yang, Weijian Guo, Dan Liu, Jiajia Yuan, Changsong Qi, Yanshuo Cao, Qiuqiong Yu, Huiming Cai, Zhi Peng, Xicheng Wang, Jun Zhou, Ming Lu, Jifang Gong, Jian Li, Yi Ba, Lin Shen

Publikováno v: Frontiers in Pharmacology, Vol 13 (2022)

Background: Simmitecan is a potent inhibitor of topoisomerase I with anti-tumor activity. This phase Ib trial was conducted to investigate the safety and anti-tumor effect of simmitecan alone or in combination with other drugs.Methods: Eligible patie

Externí odkaz: https://doaj.org/article/a4f6177649dd43ff8061081df32f3c47

Zobrazit plný text záznamu

Akademický článek

Development of the Sm14/GLA-SE Schistosomiasis Vaccine Candidate: An Open, Non-Placebo-Controlled, Standardized-Dose Immunization Phase Ib Clinical Trial Targeting Healthy Young Women

Autor: Marília Santini-Oliveira, Patrícia Machado Pinto, Tatiane dos Santos, Mônica Magno Vilar, Beatriz Grinsztejn, Valdilea Veloso, Elan C. Paes-de-Almeida, Maria A. Z. Amaral, Celso R. Ramos, Miryam Marroquin-Quelopana, Rhea Coler, Steven Reed, Marcia A. Ciol, Wilson Savino, Juçara de Carvalho Parra, Marília Sirianni dos Santos Almeida, Miriam Tendler

Publikováno v: Vaccines, Vol 10, Iss 10, p 1724 (2022)

We report the successful closure of Phase I clinical trials, comprising Phases Ia and Ib, of the vaccine candidate against human schistosomiasis: the Schistosoma mansoni 14 kDa fatty acid-binding protein (Sm14) + glucopyranosyl lipid A in squalene em

Externí odkaz: https://doaj.org/article/16b46670cb8843849883791033a3e9d2

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study

Autor: Michael Schaffer, Shalini Chaturvedi, Cuc Davis, Jan de Jong, Regina Aquino, Yasuhiro Oki, Nele Fourneau, Anas Younes, Sriram Balasubramanian

Publikováno v: Cancer Treatment and Research Communications, Vol 25, Iss , Pp 100235- (2020)

Introduction: This unplanned post-hoc analysis was based on data from the phase Ib DBL1002 study (NCT01569750) and evaluated the association between molecular biomarkers and clinical response to combined treatment with ibrutinib plus rituximab, cyclo

Externí odkaz: https://doaj.org/article/b2f5466faf1f4f18be3bbf63e3e0de8a

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání